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BORTEZOMIB AND HIGH DOSE MELPHALAN FOLLOWED BY AUTOLO-
GOUS STEM CELL TRANSPLANTATION (B-HDM/SCT) FOR THE TREAT-
MENT OF AL AMYLOIDOSIS: RESULTS OF A FEASIBILITY STUDY
Sanchorawala, V., Yanarella, L., Quillen, K., Sloan, J.M., Andrea, N.T.,
Finn, K.T., Seldin, D.C. Boston University Medical Center, Boston, MA
Aggressive treatment of AL amyloidosis with high dose melphalan
and autologous stem cell transplant (HDM/SCT) is effective in in-
ducing hematologic remission and clinical improvement. We have
observed in  500 patients treated with HDM/SCT that achieve-
ment of a hematologic complete response (CR) is a critical determi-
nant of clinical improvement and survival. A synergistic effect
between bortezomib (B) andmelphalan has been demonstrated in vi-
tro and in vivo. Thus, the combination of B and HDM is a logical
approach to study. Because of the importance of hematologic CR
in treatment outcome, we conducted a feasibility study to determine
whether addition of B to HDM/SCT would be tolerable and would
increase hematologic CR rates. Eligibility for entry into the trial re-
quired diagnosis of AL amyloidosis, age. 18 years, and adequate
performance status (SWOG# 2) and cardiopulmonary function
(LVEF. 45%, DLCO. 50%). Peripheral blood stem cells were
collected following G-CSF mobilization, with minimum yields of
2.5  106 CD34+ cells/kg required for participation in the trial. B
was administered at 1 mg/m2 on D -6, D -3, D +1, and D +4 and
HDM at 140-200 mg/m2 in two divided doses on D -2 and D -1.
From 10/2008 to 10/2009, 9 patients were enrolled (median age
53, range 46-68; median number of involved organs 2, range 1-4).
Of the 9 patients enrolled, 1 patient was removed from the protocol
because of cardiac arrhythmia during stem cell mobilization and col-
lection phase that precluded treatment with HDM/SCT. Of the 8
patients who received B-HDM/SCT, there was no treatment-related
mortality within 100 days of SCT and there were no unexpected he-
matologic or non-hematologic toxicities associated with addition of
B to HDM/SCT. The median times to neutrophil and platelet en-
graftment was D +10 and D +14 after SCT, respectively. Of 8 pa-
tients evaluable for early responses, normalization of serum free
light chain levels and ratio occurred in 7 of 8 (88%) by D +14 and
one patient achieved a 45% reduction in serum free light chain con-
centration at D +14. Of the initial 2 patients with longer follow-up,
both have achieved a hematologic CR at 6 and 9months following B-
HDM/SCT. Follow-up is ongoing and hematologic responses ap-
pear to be well-maintained. Thus, this pilot study demonstrates
that B-HDM/SCT is tolerable for selected patients with AL amy-
loidosis and leads to a high rate of hematologic responses.127
TRANSPLANT ASSOCIATED-THROMBOTIC MICROANGIOPATHY (TA-
TMA) IN PEDIATRIC NEUROBLASTOMA (NB) PATIENTS UNDERGOING
AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT): A CASE-CONTROL
STUDY IDENTIFYING EARLY CLINICAL MARKERS OF DISEASE
Laskin, B.L.1, Goebel, J.1, Davies, S.M.2, Bleesing, J.J.2, Mehta, P.A.2,
Filipovich, A.H.2, Khoury, J.C.3, Paff, Z.N.2, Jodele, S.2 1Cincinnati
Children’s Hospital Medical Center (CCHMC), OH; 2Cincinnati Child-
ren’s Hospital Medical Center, OH; 3Cincinnati Children’s Hospital Med-
ical Center, OH
Patients (pts) undergoing ASCT for NB present a unique popula-
tion to studyTA-TMAdue to their standardized chemotherapy, lack
of graft-versus host disease prophylaxis, and subsequent exposure to
radiation and cis-retinoic acid (cisRA).We performed a retrospective
case-control study of TA-TMA in NB pts who underwent ASCT at
CCHMC in the past 5 years to identify strategies for early rigorous
diagnosis. Twenty pts with high risk NB were treated with melpha-
lan, carboplatin, and etoposide followed by ASCT. Six pts were di-
agnosed with TA-TMA (4 within 25 days of ASCT) presenting
with microangiopathic hemolytic anemia, elevated lactate dehydro-genase, thrombocytopenia, hypertension (HTN), and acute kidney
injury (3 confirmedwith renal biopsy). Adenovirus, cytomegalovirus,
and influenza B were potential triggers of TA-TMA (n5 2). The 14
pts without TA-TMA served as controls. Clinical and laboratory
data were obtained for the first 30 days pre- and post-ASCT. Blood
pressure (BP) index was calculated as BP/95th percentiles for age and
height (value .15HTN). No pt had HTN pre-ASCT. Fischer’s
exact test, Wilcoxon rank sum and generalized linear models were
used for analysis. Results are shown in the Table. Proteinuria, hema-
turia, and schistocytes on blood smear were significantly associated
with TA-TMA, while blood and platelet transfusions were not.
HTN requiring therapy proved to be a very significant indicator of
TA-TMA and was identified within days of ASCT. Although serum
creatinine (SCr) did not differ significantly between groups, pts with
TA-TMA had an average 60% decrease in renal function from base-
line by nuclear glomerular filtration rate (nucGFR) post ASCT,
compared to a 30% decrease in those without TA-TMA. TA-
TMA therapy included steroids, plasmapheresis, and rituximab.
There was no TA-TMA-related mortality, but significant complica-
tions included progression to chronic dialysis (n5 1) and severe pol-
yserositis (n5 2). None of the pts with TA-TMA were able to
complete cisRA therapy. Overall, we found a 30% prevalence of
TA-TMA in transplanted NB pts. The most significant indicator
of TA-TMA was HTN. Our data are limited by their retrospective
nature and small sample size.We suggest that careful BP observation
and urinalysis monitoring will assist in the early diagnosis of TA-
TMA, while SCr measurements are of limited value. Prospective
studies are needed to confirm these results as early diagnosis and
treatment may eventually help to improve outcome.
Indicators of TA-TMA during first month post-ASCT
TA-TMA No TA-TMA
Variable (n5 6) (n5 14) P-valueProteinuria 4 (67%) 2 (15%) 0.046
Hematuria 4 (67%) 1 (8%) 0.02
Schistocytes 4 (67%) 1 (8%) 0.02
Pre-ASCT NucGFR 152.06 12.9 145.66 10.9 0.64
Post-ASCT NucGFR* 61.06 8.8 103.16 6.2 0.002
SCr (mg/dL) 0.546 0.04 0.496 0.02 0.28
Systolic BP (mm Hg) 112.26 2.5 102.26 1.6 0.004
Diastolic BP (mm Hg) 66.76 2.2 55.46 1.5 0.001
Systolic Index 1.026 0.02 0.926 0.02 0.002
Diastolic Index 0.996 0.04 0.816 0.02 0.001
Pts requiring HTN therapy 5 (83%) 3 (21%) 0.006Data n (%) or mean6 standard error. *NucGFR (ml/min/1.73 m2) done
on average 61 days post-ASCT128
IS LOW DOSE CYCLOPHOSPHAMIDE PLUS G-CSF MOBLIZATION AS EF-
FECTIVE AS MOZOBIL (PLERIXAFOR) PLUS G-CSF IN MULTIPLE MYE-
LOMA (MM) PATIENTS ELIGIBLE FOR TANDEM TRANSPLANT?
Karanes, C.1, Dagis, A.3, Wang, S.4, Krishnan, A.1, Sahebi, F.1,
Popplewell, L.1, Parker, P.1, Forman, S.1, Palmer, J.3, Kogut, N.1,
Somlo, G.2 1City of Hope, Duarte, CA; 2City of Hope, Duarte, CA;
3City of Hope, Duarte, CA; 4City of Hope, Duarte, CA
Introduction: A recent study showed 71.6% of patients who re-
ceived plerixafor plus G-CSF collected .6  106 CD34+ cells/kg
in# 2 apheresis procedures when compared to placebo plus G-
CSF.We analyzed retrospectively two tandem autologous transplant
protocols where cyclophosphamide plus G-CSF (Cy-G) was used as
mobilization therapy.
Methods: From 08/1999 to 06/2009, 120 MM patients were en-
rolled. Patients received 1.5 g/m2 of Cy followed byG-CSF. Patients
underwent consecutive leukapheresis starting on day 10 and contin-
ued until a minimum of 4x 106 CD34+/kg was collected and 6 106
CD34+/kg when possible.
Results:Median days to reach 4x 106 CD34+/kg was 1 (1-16) and for
6 106 CD34+/kg was 2 (1-16). Median days of total apheresis was 3
S206 Poster Session I(1-16). Median total CD34+/kg collected was 9.98  106 (2.55-
35.79). Twenty-six (25%) patients had prior radiation. Median age
was 54.4 years, range 29.7-66.1. Median days to neutrophil engraft-
ment was 11, range 1-16 post first transplant and 10 days (8-43) post
second transplant. Days to platelet independence after first trans-
plant was 13 days (0-71), and 12 days (0-44) after the second. We
found that time from diagnosis to collection (#7 months vs$ 7
months) impacted reaching the 6  106 CD34+ cells/kg within the
1-2 days target. Our analysis showed that patients apheresed \7
months from diagnosis were 2.6 times (CI: 1.14-5.95) more likely
to reach 6  106 CD34+/kg within the 1-2 days (p5 0.02). This re-
sult is comparable to those of DiPersio et al, Blood 113 (23):5720-
5726, 2009. Sixty-seven percent of our Cy-G patients reached 6 
106 CD34+/kg in 2 days vs 71.6% of DiPersio’s plerixafor-G pts.
Conclusion:CD34+ cell yield following Cy-Gmobilization is com-
parable to what could be obtained with plerixafor-G mobilization.
We suggest reserving plerixafor for patients with substantial delay
between diagnosis and apheresis and for those failing Cy-G mobili-
zation.129
COMPARATIVE COST-EFFECTIVENESS OF PLERIXAFOR PLUS GRANULO-
CYTE-COLONY STIMULATING FACTOR VERSUS CYCLOPHOSPHAMIDE
PLUS GRANULOCYTE-COLONY STIMULATING FOR AUTOLOGOUS PE-
RIPHERAL BLOOD STEM CELL MOBILIZATION IN PATIENTS WITH
NON-HODGKIN’S LYMPHOMA
Campen, C.J.1,3, Armstrong, E.P.1, Christian, J.A.2, Hadeed, S.2,
Yeager, A.M.3 1University of Arizona College of Pharmacy, Tucson,
AZ; 2University Medical Center, Tucson, AZ; 3Arizona Cancer Center,
University of Arizona, Tucson, AZ
Introduction: Chemomobilization of autologous peripheral blood
stem cells (PBSCs) is costly and requires substantial resource alloca-
tions. This burden has considerable effects on patients (pts), pro-
viders and payers. We performed a retrospective study to evaluate
the difference in costs and effectiveness of first-line mobilization of
autologous PBSCs with cyclophosphamide (CY; 1.5-4 gm/
m2) + G-CSF (n5 34) versus plerixafor + G-CSF (n5 8) in pts
with non-Hodgkin’s lymphoma (NHL) between 6/2006 and 8/2009.
Methods: We created a decision analytic model to estimate the
mean costs and effectiveness rates for the two regimens. This model
incorporated the minimum acceptable CD34+ cell dose for autolo-
gous PBSC transplant (PBSCT) and also incorporated adverse
events such as clinically significant nausea and vomiting, anemia,
thrombocytopenia, and hospital admissions for neutropenic fever.
The analysis was conducted from the perspective of a managed
care organization and used published literature to identify drug, lab-
oratory, and apheresis costs. A treatment success was defined as ad-
equate CD34+ dose to proceed with autologous PBSCT. We
conducted a Monte Carlo simulation of 1,000 cases.
Results: Successful PBSC mobilization occurred in 24 of 34 pts
(70.6%) in the CY group and in 7 of 8 pts (87.5%) in the plerixafor
group. Nine of the 10 pts who failed CY proceeded to second-line
plerixafor. Two pts in the CY group and one pt in the plerixafor
group underwent allogeneic transplant after failing autologous
PBSC mobilization (estimated cost $400,000; not included in analy-
sis). For CY +G-CSF, the mean cost was $20,965 and the mean ef-
fectiveness was 0.71; for plerixafor + G-CSF, the mean cost was
$19,523 and the mean effectiveness was 0.87. TheMonte Carlo sim-
ulation showed overlap between the two regimens in the 95% confi-
dence intervals in both cost and effectiveness. The incremental
analysis demonstrated that plerixafor + G-CSF dominated CY +G-
CSF (i.e., plerixafor and G-CSF was more effective and less costly)
in 69.9% of cases.
Conclusion:This decision analytic model demonstrates that plerix-
afor + G-CSF is more cost-effective than CY +G-CSF for autolo-
gous PBSC mobilization in most pts with NHL. This analysis,
conducted from a managed care perspective, does not consider the
effects of the two PBSC mobilization strategies on the quality of
life in these pts. Similar decision analyses in pts undergoing PBSC
mobilization for myeloma could also be instructive.130
A COMPARISON OF TOXICITY AND MOBILIZATION EFFICACY FOLLOW-
ING TWO DIFFERENT DOSES OF CYCLOPHOSPHAMIDE FOR MOBILIZA-
TION OF HEMATOPOIETIC STEM CELLS IN NON-HODGKIN’S
LYMPHOMA PATIENTS
Sizemore, C.A., Laporte, J., Holland, H.K., Mccollum, J., Westerman, J.,
Morris, L.E., Bashey, A., Solomon, S.R. Blood and Marrow Transplant
Program at Northside Hospital, Atlanta, GA
Background:Cyclophosphamide (Cy) (2-7 g/m2) has been shown to
be an effective regimen for hematopoietic stem cell (HSC) mobiliza-
tion in Non-Hodgkin’s Lymphoma (NHL) patients undergoing au-
tologous stem cell transplantation (ASCT). However, the optimal
dose to be used, which maximizes HSC collection yields while min-
imizing febrile neutropenia and other toxicities, remains controver-
sial. Two historical cohorts of NHL patients who received G-CSF
and Cy at dose of either 4 g/m2 (Cy4) or 2 g/m2 (Cy2) were com-
pared.
Methods: 56 patients undergoing first mobilization with Cy and
G-CSF at a single institution between 6/06 and 9/09 were retro-
spectively analyzed. The initial Cy4 patient cohort (n5 28) was
mobilized with Cy 4gm/m2 starting on Day 1 followed by G-
CSF 10ug/kg/day starting on Day 7 and continuing until comple-
tion of apheresis. Beginning in 2/08, the Cy dose was reduced to
2gm/m2 and the G-CSF start date was moved to day 4
(Cy2 n5 28). Minimal and optimal yield was defined as collection
of $2  106 and $5  106 CD34+ cells/kg respectively. Prophy-
lactic antibiotics were given for ANC \500 to reduce risk of fe-
brile neutropenia.
Results:Minimal cell dose required for ASCT was achieved in 96%
vs. 68% of Cy4 and Cy2 patients, respectively (p5 0.0116). The one
patient failing to mobilize following Cy4, later collected a minimal
cell dose following G-CSF and plerixafor. Of the 9 patients failing
to mobilize on Cy2, six of these subsequently mobilized minimal
yields following G-CSF and plerixafor. Median number of apheresis
required was significantly lower in the Cy4 patients (2 vs.3,
p5 0.0085). The proportion of patients collecting the minimal and
optimal cell dose in 2 or fewer days of apheresis was 82% vs.39%
(p5 0.0022) and 46% vs.14% (p5 0.0186), in the Cy4 and Cy2 pa-
tients respectively. Mobilization with Cy4 was associated with a sig-
nificantly higher incidence of hospital admissions due to febrile
neutropenia (32% vs. 0%, p5 0.018), which prompted the change
from Cy4 to Cy2.
Conclusions: Although Cy4 and Cy2 are both effective HSCmobi-
lizing regimens, mobilization efficacy and toxicity vary greatly. Cy4
results in higher HSC yields requiring fewer apheresis procedures,
but this benefit is offset by increased morbidity and hospitalization.
Based on the suboptimal results with Cy 4 g/m2 and Cy 2 g/m2 mo-
bilization, we are currently exploring Cytoxan 3gm/m2 in hopes to
balance mobilization safety, efficacy and cost.Cy 4gm/m21 Cy 2gm/m21
G-CSF n5 28 G-CSF n5 28 P Value% of Patients who
achieved$ 2 x106
CD341 cells/kg in day# 282% (23/28) 39% (11/28) 0.0022% of Patients who
achieved$ 5 x 106
CD341cells/kg in# 2 days46% (13/28) 14% (4/28) 0.0186% of Patients who
achieved$ 5 x106
CD341cells/kg64% (18/28) 18% (5/28) 0.009% of Patients who
collected$ 2 x 106
CD341 cells/kg96% (27/28) 68% (19/28) 0.0116Median (range) days
of collection in all
patients2 (1-5) 3 (1-7) 0.0085% Patients hospitalized
for febrile neutropenia32% (9/28) 0% 0.018
